Pipeline

Our novel gene-based medicines and other collaborative development products have the potential to transform treatment prospects, thus improving the quality and duration of life for patients with debilitating and life threatening diseases.

Loading...
Loading...
Loading...
SAR4224592 (Stargardt disease) and SAR421869 (Usher syndrome 1B) were out-licensed to Sanofi in 2009. In June 2020, Sanofi informed OXB of its intention to return these programmes

 

Loading...